Photodynamic therapy: A new approach to the treatment of choroidal neovascularization secondary to age-related macular degeneration

Current Opinion in Ophthalmology

Volumn 10, Issue 3, 1999, Pages 217-220

  Wu, Lihteh ^a   Murphy, Robert P ^a  

^a Glaser Murphy Retina Treatm Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; ETIOPURPURIN; PHOTOSENSITIZING AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; HUMAN; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA DEGENERATION; SHORT SURVEY; SUBRETINAL NEOVASCULARIZATION;

CHOROIDAL NEOVASCULARIZATION; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TREATMENT OUTCOME;

EID: 0032987211     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199906000-00011     Document Type: Short Survey

References (29)

1. 1 Ferris FL III: Senile macular degeneration: review of epidemiological features. Am J Epidemiol 1983, 118:132-151.
2. 2 Klein BE, Klein R: Cataracts and macular degeneration in older Americans. Arch Ophthalmol 1982, 100:571-573.
3. 3 Leibowitz HM, Krueger DE, Maunder LR, et al.: The Framingham Eye Study Monograph: an opnthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980, 24(suppl):428-457.
4. 4 Hyman L, Lilienfeld AM, Ferris FL III, Fine SL: Senile macular degeneration: a case control study. Am J Epidemiol 1983, 118:213-227.
5. 5 Macular Photocoagulation Study Group: Argon laser photocoagulation for neovascular maculopathy after five years. Results from randomized clinical trials. Arch Ophthalmol 1991, 109:109-114.
6. 6 Macular Photocoagulation Study Group: Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 1991, 109:1242-1257.
7. 7 Freund KB, Yannuzzi LA, Sorenson JA: Age-related macular degeneration and choroidal neovascular membranes. Am J Ophthalmol 1993, 116:786-791.
8. 8 Policard A: Etudes sur les aspects offerts par des tumeurs experimentales examinee a la lumiere de Wood. Clinical Research in Biology 1924, 91: 1423-1424.
9. 9 Dougherty TJ, Kaufman JE, Goldfarb A, et al.: Photoradiation therapy, II: cure of animal tumors with hematoporphyrin and light. J Natl Cancer Inst 1975, 55:115-120.
10. 10 Manyak MJ, Russo A, Smith PD, Glatstein E: Photodynamic therapy. J Clin Oncol 1988, 6:380-391.
11. 11 Kessel D: Sites of photosensitization by derivatives of hematoporphyrin. Photochem Photobiol 1986, 44:489-493.
12. 12 Jori G, Reddi E, Cozzini I, Tomio L: Controlled targeting of different subcellular sites by porphyrins in tumour-bearing mice. Br J Cancer 1986, 53:615-621.
13. 13 Foote CS: Photosensitized oxidation and singlet oxygen: consequences in biological systems. In Free Radicals in Biology. Edited by Pryor W. Orlando: Academic Press; 1976:85-102.
14. 14 Nseyo U: Photodynamic therapy. Urol Clin North Am 1992, 19:591-599.
15. 15 Calzavara-Pinton PG, Szeimies RM, Ortel B, Zane C: Photodynamic therapy with systemic administration of photosensitizers in dermatology. J Photochem Photobiol B 1996, 36:225-231.
16. 16 Kato H: Photodynamic therapy for lung cancer - a review of 19 years' experience. J Photochem Photobiol B 1998, 42:96-99.
17. 17 Lingua RW: Photodynamic therapy for ocular tumors. J Photochem Photobiol B 1991, 9:119-122.
18. 18 Kostron H, Obwegeser A, Jakober R: Photodynamic therapy in neurosurgery: a review. J Photochem Photobiol B 1996, 36:157-168.
19. 19 Sibille A, Lambert R, Souquet JC, et al.: Long term survival after photodynamic therapy for oesophageal cancer. Gastroenterology 1995, 108:337-344.
20. 20 Schmidt-Erfurth UM, Miller J, Sickenberg M, et al.: Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch Clin Exp Ophthalmol 1998, 236:365-374. This is the first and only report in the literature regarding the use of photosensitizing drugs for CNV in human subjects.
21. 21 Thomas EL, Rosen R, Murphy RP, et al.: Purlytin (SnET2) photodynamic therapy produces closure of subfoveal choroidal neovascularization in humans. Invest Ophthalmol Vis Sci 1998, 39:S242.
22. 22 Schmidt-Erfurth UM, Hasan T, Gragoudas E, et al.: Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994, 101:1953-1961.
23. 23 Peyman GA, Moshfeghi A, Khoobeghi B, et al.: Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2). Ophthalmic Surg Lasers 1997, 28(5):409-417.
24. 24 Kliman GH, Puliafito CA, Stern D, et al.: Phthalocyanine photodynamic therapy: new strategy for closure of choroidal neovascularization. Lasers Surg Med 1994, 15:2-10.
25. 25 Mori K, Ohta M, Sano A, et al.: Potential of photodynamic therapy with a second generation sensitizer: mono-L-aspartyl chlorin e6. Nippon Ganka Gakkai Zasshi 1997, 101:134-140.
26. 26 Miller H, Miller B: Photodynamic therapy of subretinal neovascularization in the monkey eye. Arch Ophthalmol 1993, 111:855-860.
27. 27 Husain D, Miller JW, Michaud N, et al.: Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 1996, 114:978-985.
28. 28 Kramer M, Miller JW, Michaud N, et al.: Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 1996, 103:427-428.
29. 29 Miller JW, Walsh AW, Kramer M, et al.: Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 1995, 113:810-818.